Wolfe Laboratories today announced the presentation of an abstract related to its research efforts surrounding antibody-drug conjugates (ADCs) at the 245th National Meeting of the American Chemical Society, held April 7-11 in New Orleans. The abstract details how scientists at Wolfe Laboratories, along with their University of Kansas collaborators, have found that conjugation site heterogeneity in ADCs affects the overall surface charge, which can lead to variable and unpredictable pharmaceutical performance.
